KRAS and non-small cell lung carcinoma: Moreover, the AT group improved PFS (9.8 vs 5.0 months, P < 0.001, Fig. 6C) and OS (20.0 vs 10.0 months, P < 0.001, Fig. 6D) in KRAS mutant NSCLC patients.